AstraZeneca Results Presentation Deck
FY 2020: strong and resilient double-digit performance
Key highlights
Total revenue up by 10%, continuing double-digit trajectory underpinned by focused R&D and SG&A investment
Revenue growth: new medicines¹ +33%. Oncology +24% and New CVRM² +9%. Respiratory & Immunology stable and
Emerging markets +10%, despite COVID-19³ impact to Pulmicort
Core operating profit up by 17% despite lower core 0014 (-2%)
Core EPS5 $4.02 (+18%), including 20% tax rate
Cash improving, including net cash inflow from operating activities at $4.8bn
Pipeline progress underpinning future double-digit revenue growth
ESG6: COVID-19 vaccine authorised with supplies ramping up
2021 guidance: total revenue increase by a low teens percentage, accompanied by faster growth in core EPS to $4.75 to
$5.00
Absolute values at actual exchange rates; changes at constant exchange rates (CER) and for full-year (FY) 2020, unless stated otherwise. Guidance at CER and excludes COVID-19 Vaccine AstraZeneca and Alexion.
1. Total revenue for Tagrisso, Imfinzi, Farxiga, Lynparza, Calquence, Fasenra, Enhertu, Lokelma, Koselugo, Brilinta, roxadustat, Breztri and Bevespi 2. New Cardiovascular, Renal and Metabolism comprising Brilinta, Renal and Diabetes 3. Coronavirus disease; an
infectious disease caused by a newly discovered coronavirus 4. Other operating income 5. Earnings per share 6. Environmental, social and (corporate) governance (topics).
B
6View entire presentation